Cargando…

The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies

SIMPLE SUMMARY: Monitoring the response to treatment in hematologic malignancies is essential in defining the best way to optimize patient management. In general, achieving a deeper response has been shown to lead to a better prognosis, and the techniques used to study the minimal residual disease (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colmenares, Rafael, Álvarez, Noemí, Barrio, Santiago, Martínez-López, Joaquín, Ayala, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909350/ https://www.ncbi.nlm.nih.gov/pubmed/35267616 http://dx.doi.org/10.3390/cancers14051310

Ejemplares similares

Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies
por: Sánchez, Ricardo, et al.
Publicado: (2019)

Liquid biopsies and minimal residual disease in myeloid malignancies
por: Allam, Sabine, et al.
Publicado: (2023)

Liquid biopsies and minimal residual disease in lymphoid malignancies
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
por: Honoré, Natasha, et al.
Publicado: (2021)

Liquid biopsy in hematological malignancies: current and future applications
por: Talotta, Donatella, et al.
Publicado: (2023)

Epigenetic liquid biopsies for minimal residual disease, what’s around the corner?
por: Johnston, Andrew D., et al.
Publicado: (2023)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

Editorial: Measurable residual disease in hematologic malignancies
por: Buccisano, Francesco, et al.
Publicado: (2023)

Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease
por: Figaredo, Gloria, et al.
Publicado: (2023)

P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)
por: Zamanillo, Irene, et al.
Publicado: (2023)

Liquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip
por: Khoo, Bee Luan, et al.
Publicado: (2019)

Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer
por: Stergiopoulou, Dimitra, et al.
Publicado: (2023)

Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies
por: Hocking, Jay, et al.
Publicado: (2016)

Liquid biopsies in myeloid malignancies
por: Abdulmawjood, Bilal, et al.
Publicado: (2019)

Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy
por: Trino, Stefania, et al.
Publicado: (2020)

Protein Carbonylation and Lipid Peroxidation in Hematological Malignancies
por: Rodríguez-García, Alba, et al.
Publicado: (2020)

MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD ASSESSED BY MASS SPECTROMETRY
por: Puig, Noemi
Publicado: (2022)

MEDB-74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
por: Northcott, Paul, et al.
Publicado: (2022)

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
por: Assanto, Giovanni Manfredi, et al.
Publicado: (2023)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
por: Onecha, Esther, et al.
Publicado: (2019)

The Translational Potential of Electrochemical DNA-Based Liquid Biopsy
por: Miranda-Castro, Rebeca, et al.
Publicado: (2020)

Bone Marrow Biopsies Revisited: a new dimension for hematologic malignancies
por: Harris, M.
Publicado: (1985)

Biofluids manipulation methods for liquid biopsy in minimally-invasive assays
por: Garzarelli, Valeria, et al.
Publicado: (2022)

Liquid Biopsy in Oral Cancer
por: Lousada-Fernandez, Fatima, et al.
Publicado: (2018)

Application of Non-Blood-Derived Fluid Biopsy in Monitoring Minimal Residual Diseases of Lung Cancer
por: Yan, Xing, et al.
Publicado: (2022)

Autophagy in Hematological Malignancies
por: García Ruiz, Olga, et al.
Publicado: (2022)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements
por: Cedena, Maria-Teresa, et al.
Publicado: (2020)

New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies
por: Dogliotti, Irene, et al.
Publicado: (2018)

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
por: Puig, Noemí, et al.
Publicado: (2021)

Radiomics analysis of bone marrow biopsy locations in [(18)F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma
por: Milara, Eva, et al.
Publicado: (2023)

Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors
por: Albitar, Maher, et al.
Publicado: (2023)

Immune-Mediated Cutaneous Paraneoplastic Syndromes Associated With Hematologic Malignancies: Skin as a Mirror of Hematologic Neoplasms
por: Alvarez-Payares, Jose C, et al.
Publicado: (2021)

Liquid Biopsy for Solid Ophthalmic Malignancies: An Updated Review and Perspectives
por: Martel, Arnaud, et al.
Publicado: (2020)

Liquid biopsies to distinguish malignant from benign pulmonary nodules
por: Tao, Rui, et al.
Publicado: (2021)

Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies
por: Palanca-Ballester, Cora, et al.
Publicado: (2021)

Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer
por: Rodriguez-Casanova, Aitor, et al.
Publicado: (2021)

Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer
por: McGuire, Anna L, et al.
Publicado: (2020)

P845: IDENTIFICATION OF MULTIPLE MYELOMA BIOMARKERS VIA LIQUID BIOPSY BASED ON CELL-FREE DNA USING A CAPTURE-HYBRIDIZATION PANEL
por: Buenache Cuenda, N., et al.
Publicado: (2022)

PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.
por: Sánchez-Redondo, Noemí Álvarez, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_holac2c6tu164vs6fqcokhni96